Tumor Testing Laboratories in ComboMATCH

For interested patients, molecular eligibility for the treatment trials will be determined using archival tumor tissue specimens analyzed by genetic testing laboratories designated by the National Cancer Institute (NCI) to participate in ComboMATCH (see below). Physicians routinely order these tests to guide clinical care for their patients. Only tumor assay results will be accepted for ComboMATCH. Clinical reports using ctDNA/ liquid biopsy assay results cannot be accepted at this time.

ComboMATCH-designated labs will inform oncologists at participating trial sites when patients' tumor test results show abnormalities being targeted by the drug combinations in the study. During the initial registration step, a patient's oncologist will review the test results, along with other clinical information, to determine if they are eligible for one of the treatment trials.

Nearly 40 commercial and academic labs are participating in ComboMATCH, as shown below and on this Downloadable Spreadsheet.

Commercial Designated Laboratories

Click on the lab name below to access the company website. Patients and physicians may send emails directly to commercial labs to request a review of a tumor test or seek general information. There is no need to contact the NCI or the ECOG-ACRIN Cancer Research Group.

Academic Designated Laboratories

In general, these labs, which are located in universities and at the NCI, identify potential trial candidates from their patient populations.

  • Cedars-Sinai Medical Center โ€“ Molecular Pathology Laboratory
  • Children's Hospital of Philadelphia
  • City of Hope National Medical Center โ€“ Clinical Molecular Diagnostics Laboratory
  • Columbia University โ€“ Laboratory of Personalized Genomic Medicine in the Department of Pathology and Cell Biology - Activating Soon
  • Johns Hopkins Genomics
  • Knight Diagnostic Laboratories at Oregon Health & Science University
  • Memorial Sloan Kettering Cancer Center
  • Molecular Characterization Laboratory at the Frederick National Laboratory for Cancer Research
  • National Cancer Institute โ€“ Laboratory of Pathology
  • Providence Genomics
  • Stanford Health Care โ€“ Molecular Genetic Pathology Laboratory
  • Texas Children's Hospital
  • The University of Texas MD Anderson Cancer Center
  • University of California San Francisco
  • University of Chicago โ€“ Clinical Genomics Laboratory
  • University of Colorado โ€“ Colorado Molecular Correlates Laboratory
  • University of Illinois Chicago 4
  • University of Michigan โ€“ Michigan Medicine Molecular Diagnostics Laboratory - Activating Soon
  • Weill Cornell Medicine โ€“ Clinical Genomics Laboratory


1 These laboratories can only provide patient referrals for treatment trials that include Insertion-Deletion Mutations (Indels) and Single Nucleotide Variant (SNV) inclusions/exclusions. Referrals for Copy Number Variants (CNVs) will not be accepted at this time.

2 Effective July 6, 2023, Quest Diagnostics discontinued testing with the Med Fusion Clinical Labs 50SEQ Assay from the Lewisville, Texas facility. However, Med Fusion Clinical Labs 50SEQ assay results prior to July 6, 2023, will be accepted for ComboMATCH. Clinical reports using the Quest Advanced Diagnostics Solid Tumor Core Panel test from the San Juan Capistrano, California, location will not be accepted at this time.

3 Quest Diagnostics test results will not be accepted from patients tested in the following states: Alaska, Iowa, Louisiana, Minnesota, New Hampshire, Vermont, and Washington.

4 These labloratories can only provide patient referrals for treatment trials that include Copy Number Variants (CNVs) and Single Nucleotide Variant (SNV) inclusions/exclusions. Referrals for Insertion-Deletion Mutations (Indels) will not be accepted at this time.

5 Only assay results from the FoundationOneยฎCDx assay will be accepted for ComboMATCH. Clinical reports using the FoundationOneยฎLiquid CDx assay results cannot be accepted.

About NCI Designation

All ComboMATCH-designated laboratories are accredited by CLIA (Clinical Laboratory Improvement Amendments), a federal regulatory program. The NCI previously validated these laboratories to perform high-quality next-generation sequencing (NGS) assays for ComboMATCH after the labs responded to solicitations in the Federal Register. The process is now closed.

About FDA Approval

Eligibility for a ComboMATCH trial may have been determined in part based on a laboratory-developed test that has not been reviewed or approved by the FDA.


  • Patients interested in learning more about ComboMATCH should start by speaking with their doctor or healthcare team
  • Reach out to the Contact Center at the National Cancer Institute, where trained specialists answer cancer-related questions in English and Spanish
  • Study personnel with questions about ComboMATCH may send an email to the National Cancer Institute
ECOG-ACRIN Cancer Research Group